CC-486 (Oral Azacitidine) Maintenance Therapy Is Well Tolerated after Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
Year: 2016
Type: conference-abstract
Abstract: Relapse and graft vs host disease (GvHD) following alloHSCT are the major causes of treatment (Tx) failure in patients (pts) with MDS and AML. Azacitidine may reduce risk of relapse and GVHD post-allograft (Platzbecker, 2012; de Lima, 2010). Azacitidine up-regulates putative tumor antigens, inducing a CD8+ T cell response that could augment a graft vs leukemia effect (Craddock, 2015). Reported here are interim results of an ongoing phase I/II dose-finding study of CC-486 (oral azacitidine) maintenance Tx post-alloHSCT.
Institutions: University Hospitals Seidman Cancer Center, Case Western Reserve University, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Fred Hutch Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Celgene (United States), Queen Elizabeth Hospital Birmingham
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2469723064